Skip to content
Seagry Consultancy
Menu

Common purpose / Safety systems

Medicines and devices

Harm from mesh, valproate, controlled drugs and insulin sits alongside weak product regulation, poor consent, and registries that were recommended long before they existed.

10 reviews · 13 recommendations

Reviews, most recent first

  1. 2026
    Thirlwall Inquiry

    Lady Justice Thirlwall

  2. 2025
  3. 2024
    Cass review

    Dr Hilary Cass

  4. 2024
    Hughes report

    Dr Henrietta Hughes

  5. 2024
    Infected Blood Inquiry

    Sir Brian Langstaff

  6. 2020
    Cumberlege review

    Baroness Cumberlege

  7. 2018
    Gosport

    Bishop James Jones

  8. 2015
    Penrose Inquiry

    The Rt Hon Lord Penrose

  9. 2005
    Shipman Inquiry

    Dame Janet Smith

  10. 1994
    Clothier (Allitt)

    Sir Cecil Clothier

What they asked for

  1. Thirlwall Inquiry2026Awaiting response

    Restrict and record access to insulin, and make national guidance on investigating hypoglycaemia mandatory.

    NHS trusts

  2. Move the Patient Safety Commissioner's medicines role to the MHRA, and wider patient-experience work into DHSC.

    DHSC

  3. Cass review2024Accepted

    Restrict puberty-suppressing hormones to research settings until the evidence is stronger.

    NHS England

  4. Hughes report2024Partly done

    Set up a financial redress scheme for pelvic mesh and for sodium valproate in pregnancy.

    Government

  5. Hughes report2024Partly done

    Provide non-financial support, including specialist services and help with accessing records.

    NHS

  6. Infected Blood Inquiry2024In progress

    Pay compensation through a scheme that is independent and prompt.

    UK government

  7. Cumberlege review2020Not implemented

    Create an independent redress agency.

    Government

  8. Cumberlege review2020Partly done

    Build registries for devices and a clearer record of conflicts of interest and industry payments.

    MHRA and NHS

  9. Cumberlege review2020Partly done

    Reform the MHRA so that it looks harder for harm after a product is in use, with patients in the work.

    MHRA

  10. Gosport2018Partly done

    Govern controlled drugs so that one clinician's practice cannot drift without being seen.

    NHS trusts

  11. Penrose Inquiry2015Partly done

    Test those who may have been infected and offer them care.

    NHS Scotland

  12. Penrose Inquiry2015Superseded

    The question of proper compensation was left for the later UK inquiry.

    Government

  13. Shipman Inquiry2005Accepted

    Tighten the governance of controlled drugs.

    Government and NHS